SGIOY:OTCMKTS
Shionogi 2 ADR Representing 1 Ord Shs
$9.18
arrow_upward
+0.55%(+0.050) 1D
Okt 16, 4:00:00 PM GMT-4 · USD
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa SGIOY...
Buksan
$9.36
Mataas
$9.36
Mababa
$9.18
Mkt. cap
2.61T
Avg. na dami
175.16K
Dami
163.94K
Mataas nang 52-wk
$12.00
Mababa nang 52-wk
$7.83
Beta
0.07
Mga natitirang share
1.78B
Bilang ng mga empleyado
6K
Buksan
$9.36
Mataas
$9.36
Mababa
$9.18
Mkt. cap
2.61T
Avg. na dami
175.16K
Dami
163.94K
Mataas nang 52-wk
$12.00
Mababa nang 52-wk
$7.83
Beta
0.07
Mga natitirang share
1.78B
Bilang ng mga empleyado
6K
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
Bloomberg.com
·
22 oras ang nakalipas
S&P 500 Steady as Warsh Boosts Expectations of Rate Hold
Reuters
·
1 araw ang nakalipas
Wall Street tumbles as worries about AI trade and high oil prices weigh
MarketWatch
·
1 buwan ang nakalipas
The S&P 500 keeps climbing on days when stocks broadly struggle. Here’s what’s going on.
The Motley Fool
·
6 araw ang nakalipas
VOO Doesn't Hold SpaceX, Taiwan Semiconductor, Samsung Electronics, SK Hynix, or ASML. Meet the Vanguard ETF That Does.
Profile
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.
On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
Tungkol sa Shionogi 2 ADR Representing 1 Ord Shs